[{"id":"2c7aea1c-f022-40ea-9369-e14f70ce02b7","acronym":"UNICAB","url":"https://clinicaltrials.gov/study/NCT03685448","created_at":"2021-03-03T14:55:51.063Z","updated_at":"2024-07-02T16:36:17.039Z","phase":"Phase 2","brief_title":"ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)","source_id_and_acronym":"NCT03685448 - UNICAB","lead_sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","biomarkers":" TFE3","pipe":" | ","alterations":" TFE3 translocation","tags":["TFE3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TFE3 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/11/2019","start_date":" 04/11/2019","primary_txt":" Primary completion: 10/30/2022","primary_completion_date":" 10/30/2022","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2022-02-16"},{"id":"a1cd2191-9709-49a0-948c-443b92aa49a9","acronym":"UNISoN","url":"https://clinicaltrials.gov/study/NCT03177239","created_at":"2021-03-03T14:55:22.558Z","updated_at":"2025-02-25T14:26:25.805Z","phase":"Phase 2","brief_title":"Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)","source_id_and_acronym":"NCT03177239 - UNISoN","lead_sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","biomarkers":" TFE3","pipe":" | ","alterations":" TFE3 translocation","tags":["TFE3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TFE3 translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 10/19/2017","start_date":" 10/19/2017","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2022-02-16"}]